{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:35:39Z","timestamp":1790116539300,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5552-1","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:02:41Z","timestamp":1554940961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-9434","authenticated-orcid":false,"given":"Shing Fung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Ying","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon","family":"Spika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"5552_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\/'s Haematological malignancy research network. Br J Cancer. 2015;112:1575\u201384.","journal-title":"Br J Cancer"},{"key":"5552_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3816\/CLM.2009.n.042","volume":"9","author":"H Mani","year":"2009","unstructured":"Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009;9:206\u201316.","journal-title":"Clin Lymphoma Myeloma"},{"key":"5552_CR3","doi-asserted-by":"publisher","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","volume":"25","author":"DA Eichenauer","year":"2014","unstructured":"Eichenauer DA, Engert A, Andr\u00e9 M, Federico M, Illidge T, Hutchings M, Ladetto M. Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2014;25:iii70\u20135.","journal-title":"Ann Oncol"},{"key":"5552_CR4","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","volume":"23","author":"A Engert","year":"2005","unstructured":"Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Duhmke E, Muller-Hermelink K, Diehl V. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's study group. J Clin Oncol. 2005;23:5052\u201360.","journal-title":"J Clin Oncol"},{"key":"5552_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdh012","volume":"15","author":"A Levis","year":"2004","unstructured":"Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15:123\u20138.","journal-title":"Ann Oncol"},{"key":"5552_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","volume":"119","author":"GL Stark","year":"2002","unstructured":"Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR. Northern region lymphoma G: Hodgkin's disease in the elderly: a population-based study. Br J Haematol. 2002;119:432\u201340.","journal-title":"Br J Haematol"},{"key":"5552_CR7","unstructured":"Ries LAG KC, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer statistics review, 1973-1996, National Cancer Institute. Bethesda, MD, 1999."},{"key":"5552_CR8","volume-title":"Hodgkin lymphoma: a comprehensive update on diagnostics and clinics","author":"A Engert","year":"2010","unstructured":"Engert A, Horning SJ. Hodgkin lymphoma: a comprehensive update on diagnostics and clinics. Berlin Heidelberg: Springer; 2010."},{"key":"5552_CR9","unstructured":"American Cancer Society. Cancer Statistics Center Analysis Tool. 2018. https:\/\/cancerstatisticscenter.cancer.org\/#!\/data-analysis\/IncRate . Accessed 30 Apr 2018."},{"key":"5552_CR10","unstructured":"Cancer Research UK. Hodgkin lymphoma statistics 2018 http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma . Accessed 30 Apr 2018."},{"key":"5552_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrclinonc.2010.71","volume":"7","author":"V Diehl","year":"2010","unstructured":"Diehl V. Hematology: are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol. 2010;7:301\u20132.","journal-title":"Nat Rev Clin Oncol"},{"key":"5552_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2016.05.003","volume":"53","author":"PJ Br\u00f6ckelmann","year":"2016","unstructured":"Br\u00f6ckelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53:155\u201364.","journal-title":"Semin Hematol"},{"key":"5552_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/PPO.0b013e31819e30d7","volume":"15","author":"AK Ng","year":"2009","unstructured":"Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009;15:164\u20138.","journal-title":"Cancer J"},{"key":"5552_CR14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"5552_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040620711402414","volume":"2","author":"DJ Straus","year":"2011","unstructured":"Straus DJ. Long-term survivorship at a Price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patient. Therapeutic Advances in Hematology. 2011;2:111\u20139.","journal-title":"Therapeutic Advances in Hematology"},{"key":"5552_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","volume":"2016","author":"FE Leeuwen van","year":"2016","unstructured":"van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016:323\u201330.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5552_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640\u201352.","journal-title":"N Engl J Med"},{"key":"5552_CR18","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506\u201314.","journal-title":"N Engl J Med"},{"key":"5552_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cncr.24819","volume":"116","author":"I Biasoli","year":"2010","unstructured":"Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Divine M, Brice P. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group. Cancer. 2010;116:631\u20139.","journal-title":"Cancer"},{"key":"5552_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1999;17:776\u201383.","journal-title":"J Clin Oncol"},{"key":"5552_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/COC.0b013e31820dbc2c","volume":"36","author":"S Bose","year":"2013","unstructured":"Bose S, Ganesan C, Pant M, Lai C, Tabbara IA. Lymphocyte-predominant Hodgkin disease: a comprehensive overview. Am J Clin Oncol. 2013;36:91\u20136.","journal-title":"Am J Clin Oncol"},{"key":"5552_CR22","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa064601","volume":"357","author":"C Ferme","year":"2007","unstructured":"Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357:1916\u201327.","journal-title":"N Engl J Med"},{"key":"5552_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1111961","volume":"366","author":"RM Meyer","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366:399\u2013408.","journal-title":"N Engl J Med"},{"key":"5552_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875\u201385.","journal-title":"N Engl J Med"},{"key":"5552_CR25","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/sj.leu.2404900","volume":"21","author":"D Ribatti","year":"2007","unstructured":"Ribatti D, Nico B, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. Leukemia. 2007;21:2085\u20139.","journal-title":"Leukemia"},{"key":"5552_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1634\/theoncologist.2012-0034","volume":"17","author":"YW Koh","year":"2012","unstructured":"Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871\u201380.","journal-title":"Oncologist"},{"key":"5552_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3816\/CLM.2006.n.046","volume":"7","author":"L Shivakumar","year":"2006","unstructured":"Shivakumar L, Ansell S. Targeting B-lymphocyte stimulator\/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma. 2006;7:106\u20138.","journal-title":"Clin Lymphoma Myeloma"},{"key":"5552_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1189\/jlb.1105656","volume":"80","author":"C Lamagna","year":"2006","unstructured":"Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006;80:705\u201313.","journal-title":"J Leukoc Biol"},{"key":"5552_CR29","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439\u201353.","journal-title":"J Exp Med"},{"key":"5552_CR30","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","volume":"70","author":"AL Doedens","year":"2010","unstructured":"Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70:7465\u201375.","journal-title":"Cancer Res"},{"key":"5552_CR31","first-page":"5","volume":"111","author":"H Mocikova","year":"2010","unstructured":"Mocikova H. Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas. Prague Med Rep. 2010;111:5\u201311.","journal-title":"Prague Med Rep"},{"key":"5552_CR32","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1182\/blood.V100.12.3935","volume":"100","author":"GZ Rassidakis","year":"2002","unstructured":"Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, et al. BCL-2 expression in Hodgkin and reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100:3935\u201341.","journal-title":"Blood"},{"key":"5552_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","volume":"128","author":"TW Kelley","year":"2007","unstructured":"Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958\u201365.","journal-title":"Am J Clin Pathol"},{"key":"5552_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clml.2014.10.001","volume":"15","author":"A Belotti","year":"2015","unstructured":"Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE. Peripheral blood lymphocyte\/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk. 2015;15:208\u201313.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5552_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejim.2014.01.019","volume":"25","author":"O Markovic","year":"2014","unstructured":"Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count\/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med. 2014;25:296\u2013302.","journal-title":"Eur J Intern Med"},{"key":"5552_CR36","first-page":"101042831770550","volume":"39","author":"N Li","year":"2017","unstructured":"Li N, Zhang L, Song HL, Zhang J, Weng HW, Zou LQ. Prognostic impact of absolute lymphocyte count\/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer\/T-cell lymphoma. Tumour Biol. 2017;39:1010428317705503.","journal-title":"Tumour Biol"},{"key":"5552_CR37","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.3324\/haematol.2012.064576","volume":"97","author":"A Romano","year":"2012","unstructured":"Romano A, Vetro C, Donnarumma D, Forte S, Ippolito M, Di Raimondo F. Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte\/monocyte ratio at diagnosis in classical Hodgkin\u2019s lymphoma. Haematologica. 2012;97:e21\u20133.","journal-title":"Haematologica"},{"key":"5552_CR38","doi-asserted-by":"crossref","first-page":"31926","DOI":"10.18632\/oncotarget.7876","volume":"7","author":"L Gu","year":"2016","unstructured":"Gu L, Li H, Chen L, Ma X, Li X, Gao Y, Zhang Y, Xie Y, Zhang X. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:31926\u201342.","journal-title":"Oncotarget"},{"key":"5552_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"5552_CR40","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.","journal-title":"PLoS Med"},{"key":"5552_CR41","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama. 2000;283:2008\u201312.","journal-title":"Jama"},{"key":"5552_CR42","unstructured":"Higgins JPT GSe: Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The Cochrane Collaboration, 2011. Available from http:\/\/handbook-5-1.cochrane.org\/ . Accessed 30 Apr 2018."},{"key":"5552_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280\u20136.","journal-title":"Ann Intern Med"},{"key":"5552_CR44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"5552_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"5552_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"5552_CR47","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867\u201372.","journal-title":"Lancet"},{"key":"5552_CR48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"issue":"jul22 1","key":"5552_CR49","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"J. A. C. Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"5552_CR50","unstructured":"StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP."},{"key":"5552_CR51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2141.2012.09067.x","volume":"157","author":"LF Porrata","year":"2012","unstructured":"Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012a;157:321\u201330.","journal-title":"Br J Haematol"},{"key":"5552_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3324\/haematol.2011.050138","volume":"97","author":"LF Porrata","year":"2012","unstructured":"Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012b;97:262\u20139.","journal-title":"Haematologica"},{"key":"5552_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hon.2155","volume":"33","author":"YW Koh","year":"2015","unstructured":"Koh YW, Jung SJ, Yoon DH, Suh C, Cha HJ, Go H, Kim JE, Kim CW, Huh J. The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age. Hematol Oncol. 2015;33:133\u201340.","journal-title":"Hematol Oncol"},{"key":"5552_CR54","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","volume":"90","author":"T Tadmor","year":"2015","unstructured":"Tadmor T, Bari A, Marcheselli L, Sacchi S, Aviv A, Baldini L, et al. Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patients. Mayo Clin Proc. 2015;90:756\u201364.","journal-title":"Mayo Clin Proc"},{"key":"5552_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12185-015-1884-z","volume":"103","author":"Z Simon","year":"2016","unstructured":"Simon Z, Barna S, Miltenyi Z, Husi K, Magyari F, Jona A, Garai I, Nagy Z, Ujj G, Szerafin L, Illes A. Combined prognostic value of absolute lymphocyte\/monocyte ratio in peripheral blood and interim PET\/CT results in Hodgkin lymphoma. Int J Hematol. 2016;103:63\u20139.","journal-title":"Int J Hematol"},{"key":"5552_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1634\/theoncologist.2015-0251","volume":"21","author":"TP Vassilakopoulos","year":"2016","unstructured":"Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, Petevi K, Pangalis GA, Moschogiannis M, et al. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and Dacarbazine or equivalent regimens. Oncologist. 2016;21:343\u201353.","journal-title":"Oncologist"},{"key":"5552_CR57","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2015.1110745","volume":"57","author":"LR Jakovic","year":"2016","unstructured":"Jakovic LR, Mihaljevic BS, Andjelic BM, Bogdanovic AD, Perunicic Jovanovic MD, Babic DD, Bumbasirevic VZ. Prognostic value of lymphocyte\/monocyte ratio in advanced Hodgkin lymphoma: correlation with international prognostic score and tumor associated macrophages. Leuk Lymphoma. 2016;57:1839\u201347.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"5552_CR58","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","volume":"97","author":"Alessandra Romano","year":"2018","unstructured":"Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol. 2018;97:1009\u201318. http:\/\/dx.doi.org\/10.1007\/s00277-018-3276-y .","journal-title":"Annals of Hematology"},{"key":"5552_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant Protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29:313\u201326.","journal-title":"J Interf Cytokine Res"},{"key":"5552_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2019","volume":"31","author":"T Tadmor","year":"2013","unstructured":"Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma\u2014possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2013;31:65\u201371.","journal-title":"Hematol Oncol"},{"key":"5552_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0b013e318242169f","volume":"35","author":"AJ Montero","year":"2012","unstructured":"Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35:107\u201315.","journal-title":"J Immunother"},{"key":"5552_CR62","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Di Raimondo F. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168:689\u2013700.","journal-title":"Br J Haematol"},{"key":"5552_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","volume":"95","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Nievelstein RAJ, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95:1\u20139.","journal-title":"Ann Hematol"},{"key":"5552_CR64","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/0002-9343(75)90497-0","volume":"58","author":"E Diaz-Jauanen","year":"1975","unstructured":"Diaz-Jauanen E, Strickland RG, Williams RC. Studies of human lymphocytes in the newborn and the aged. Am J Med. 1975;58:620\u20138.","journal-title":"Am J Med"},{"key":"5552_CR65","doi-asserted-by":"publisher","first-page":"h4419","DOI":"10.1136\/bmj.h4419","volume":"351","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick P. What is publication bias in a meta-analysis? Bmj. 2015;351:h4419.","journal-title":"Bmj"},{"key":"5552_CR66","doi-asserted-by":"publisher","first-page":"h4718","DOI":"10.1136\/bmj.h4718","volume":"351","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. Bmj. 2015;351:h4718.","journal-title":"Bmj"},{"key":"5552_CR67","doi-asserted-by":"publisher","first-page":"b4184","DOI":"10.1136\/bmj.b4184","volume":"339","author":"H Hemingway","year":"2009","unstructured":"Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ. 2009;339:b4184.","journal-title":"BMJ"},{"key":"5552_CR68","unstructured":"Biasoli I, Castro N, Delamain M, Silveira T, Farley J, Sim\u00f5es BP, et al: Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian prospective registry. Hematological Oncology:n\/a-n\/a."},{"key":"5552_CR69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/0971-5851.171550","volume":"36","author":"RN Maddi","year":"2015","unstructured":"Maddi RN, Linga VG, Iyer KK, Chowdary JS, Gundeti S, Digumarti R, Paul TR. Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution. Indian J Med Paediatr Oncol. 2015;36:255\u201360.","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5552-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T01:18:57Z","timestamp":1607217537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5552-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5552"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5552-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"27 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses were based on previous published studies, thus no ethical approval and patient consent are required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"338"}}